Publications by authors named "A C Darke"
Article Synopsis
- Premenopausal women with early-stage, high-risk hormone receptor-positive breast cancer often stop their adjuvant endocrine therapy (ET) due to side effects, which can lead to higher chances of recurrence and mortality.
- The study will enroll 540 participants to test if Active Symptom Monitoring (ASM) combined with patient education can help reduce early discontinuation of ET by tracking symptoms through weekly check-ins.
- The main goal is to see if better management of ET-related side effects increases adherence to treatment, improving overall cancer outcomes and quality of life over the course of 72 weeks.
Background: Cancer-related financial hardship is a side effect of cancer diagnosis and treatment, and affects both patients and caregivers. Although many oncology clinics have increased financial navigation services, few have resources to proactively provide financial counseling and assistance to families affected by cancer before financial hardship occurs. As part of an ongoing randomized study testing a proactive financial navigation intervention, S1912CD, among sites of the National Cancer Institute Community Oncology Research Program (NCORP), we conducted a baseline survey to learn more about existing financial resources available to patients and caregivers.
View Article and Find Full Text PDFImportance: A key issue for the adjuvant treatment of patients with melanoma is the assessment of the effect of treatment on relapse, survival, and quality of life (QOL).
Objective: To compare QOL in patients with resected melanoma at high risk for relapse who were treated with adjuvant pembrolizumab vs standard of care with either ipilimumab or high-dose interferon α 2b (HDI).
Design, Setting, And Participants: The S1404 phase 3 randomized clinical trial was conducted by the SWOG Cancer Research Network at 211 community/academic sites in the US, Canada, and Ireland.
Importance: Aromatase inhibitors (AIs) have proven efficacy for the treatment of hormone-sensitive breast cancer; however, arthralgias (pain and stiffness) contribute to nonadherence with therapy for more than 50% of patients.
Objective: To examine the effect of acupuncture in reducing AI-related joint pain through 52 weeks.
Design, Setting, And Participants: A randomized clinical trial was conducted at 11 sites in the US from May 1, 2012, to February 29, 2016, with a scheduled final date of follow-up of September 5, 2017, to compare true acupuncture (TA) with sham acupuncture (SA) or waiting list control (WC).